Sugi Predict

Sugi Predict / Compounds / SCHEMBL5957461

SCHEMBL5957461

SCHEMBL5957461

O=C(OCc1ccccc1)c1cn2c(=O)n(Cc3ccccc3)c(=O)cc2s1

nearest known ligand 1.00 ✓ in ChEMBL — recovers established targets

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
▸ MMP13 P45452 1/20 1.00
▸ KMT2A Q03164 3/20 0.43
▸ SMN1; SMN2 Q16637 2/20 0.43
▸ KDM4E B2RXH2 1/20 0.43
▸ TRPA1 O75762 6/20 0.41
▸ SLC6A2 P23975 1/20 0.40
▸ SLC6A3 Q01959 1/20 0.40
▸ TDP1 Q9NUW8 1/20 0.40
▸ HPGD P15428 1/20 0.39
▸ KAT2B Q92831 1/20 0.39
▸ MAPK1 P28482 2/20 0.38
▸ NPSR1 Q6W5P4 1/20 0.38
▸ ALDH1A1 P00352 4/20 0.38
▸ LMNA P02545 2/20 0.37
▸ NPC1 O15118 1/20 0.37
▸ MAPT P10636 1/20 0.37
▸ RAB9A P51151 1/20 0.37
▸ MEN1 O00255 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5957475 0.94 MMP13 (0.88) MMP13KMT2ASMN1; SMN2KDM4ETRPA1
Hydrochloric Acid SCHEMBL5957471 0.93 MMP13 (0.86) MMP13KMT2ASMN1; SMN2KDM4ETRPA1
SCHEMBL5957565 0.87 MMP13 (0.78) MMP13KMT2ASMN1; SMN2KDM4ETRPA1
SCHEMBL5957360 0.86 MMP13 (0.74) MMP13KMT2ASMN1; SMN2KDM4ETRPA1
SCHEMBL5957708 0.81 MMP13 (0.67) MMP13KMT2ASMN1; SMN2KDM4ETRPA1
SCHEMBL5957700 0.80 MMP13 (0.66) MMP13KMT2ASMN1; SMN2KDM4ETRPA1
SCHEMBL5957316 0.78 TRPA1 (0.67) MMP13KMT2ATRPA1MEN1
SCHEMBL7012216 0.76 MMP13 (0.61) MMP13KMT2ASMN1; SMN2KDM4ETRPA1
SCHEMBL5957834 0.76 MMP13 (0.61) MMP13KMT2ASMN1; SMN2KDM4ETRPA1
SCHEMBL5957603 0.76 MMP13 (0.61) MMP13KMT2ASMN1; SMN2KDM4ESLC6A2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 38 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20060040957-A1 BICYCLIC PYRIMIDINE MATRIX METALLOPROTEINASE INHIBITORS WARNER-LAMBERT COMPANY 2006-02-23 — — US claimed
EP-1362054-A1 BICYCLIC PYRIMIDINE MATRIX METALLOPROTEINASE INHIBITORS Warner-Lambert Company LLC (US) 2003-11-19 — — EP claimed
WO-2002064599-A1 BICYCLIC PYRIMIDINE MATRIX METALLOPROTEINASE INHIBITORS WARNER-LAMBERT COMPANY LLC (US) 2002-08-22 — — WO claimed
CN-113395114-B Optical module, data center system and data transmission method 华为技术有限公司 2022-09-16 — — CN disclosed
CN-112953641-B OPEN-WDM device and control method 长飞光纤光缆股份有限公司 2022-03-18 — — CN disclosed
US-20210254056-A1 IDENTIFICATION AND TARGETED MODULATION OF GENE SIGNALING NETWORKS CAMP4 THERAPEUTICS CORPORATION 2021-08-19 — — US disclosed
US-10980860-B2 Diagnosis, prevention and treatment of diseases of the joint ASCENDIS PHARMA A/S (DK) 2021-04-20 — — US disclosed
EP-2906245-B1 DIAGNOSIS, PREVENTION AND TREATMENT OF DISEASES OF THE JOINT ASCENDIS PHARMA AS (DK) 2021-01-13 — — EP disclosed
US-20190262426-A1 Hydrogel-Linked IL-1ra Prodrug ASCENDIS PHARMA A/S (DK) 2019-08-29 — — US disclosed
US-20190192691-A1 REGULATED BIOCIRCUIT SYSTEMS OBSIDIAN THERAPEUTICS, INC. 2019-06-27 — — US disclosed
EP-3054982-B1 HYDROGEL-LINKED IL-1RA PRODRUG ASCENDIS PHARMA AS (DK) 2019-05-01 — — EP disclosed
WO-2004007024-A1 COMBINATION OF AN ALLOSTERIC INHIBITOR OF MATRIX METALLOPROTEINASE-13 WITH A SELECTIVE INHIBITOR OF CYCLOOXYGENASE-2 THAT IS NOT CELECOXIB OR VALDECOXIB WARNER-LAMBERT COMPANY LLC (US) 2004-01-22 — — WO disclosed
WO-2004006931-A2 PHARMACEUTICAL COMPOSTIONS COMPRISING AN ALLOSTERIC CARBOXYLIC INHIBITOR OF MATRIX METALLOPROTEINASE-13 AND A SELECTIVE INHIBITOR OF CYCLOOXYGENASE-2 WARNER-LAMBERT COMPANY LLC (US) 2004-01-22 — — WO disclosed
WO-2004006912-A2 COMBINATION OF AN ALLOSTERIC CARBOXYLIC INHIBITOR OF MATRIX METALLOPROTEINASE-13 WITH CELECOXIB OR VALDECOXIB WARNER-LAMBERT COMPANY LLC (US) 2004-01-22 — — WO disclosed
WO-2004006931-A2 PHARMACEUTICAL COMPOSTIONS COMPRISING AN ALLOSTERIC CARBOXYLIC INHIBITOR OF MATRIX METALLOPROTEINASE-13 AND A SELECTIVE INHIBITOR OF CYCLOOXYGENASE-2 WARNER-LAMBERT COMPANY LLC (US) 2004-01-22 — — WO disclosed
EP-1362054-A1 BICYCLIC PYRIMIDINE MATRIX METALLOPROTEINASE INHIBITORS Warner-Lambert Company LLC (US) 2003-11-19 — — EP disclosed
EP-1361873-A2 MATRIX METALLOPROTEINASE INHIBITORS Warner-Lambert Company LLC (US) 2003-11-19 — — EP disclosed
US-20030078276-A1 Matrix metalloproteinase inhibitors ANDRIANJARA CHARLES (FR) 2003-04-24 — — US disclosed
WO-2002064080-A2 MATRIX METALLOPROTEINASE INHIBITORS WARNER-LAMBERT COMPANY LCC (US) 2002-08-22 — — WO disclosed
WO-2002064599-A1 BICYCLIC PYRIMIDINE MATRIX METALLOPROTEINASE INHIBITORS WARNER-LAMBERT COMPANY LLC (US) 2002-08-22 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060040957-A1 BICYCLIC PYRIMIDINE MATRIX METALLOPROTEINASE INHIBITORS MMP13, MMP25, MMP15 MMP13 1/4885KMT2A 3012/4885SMN1; SMN2 1727/4885
US-20030078276-A1 Matrix metalloproteinase inhibitors MMP13, MMP25, MMP12 MMP13 1/4885KMT2A 2963/4885SMN1; SMN2 1745/4885
US-10980860-B2 Diagnosis, prevention and treatment of diseases of the joint TNF, ADAMTS5, ADAMTS1 MMP13 12/4885KMT2A 3627/4885SMN1; SMN2 1995/4885
US-20190262426-A1 Hydrogel-Linked IL-1ra Prodrug IL1A, IL1R1, IL1B MMP13 234/4885KMT2A 2894/4885SMN1; SMN2 3745/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.